​

ImageneBio (IMA) Stock Forecast, Price Target & Predictions

OverviewFinancialsChart

IMA Stock Forecast

ImageneBio (IMA) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $1.33, with a high of $1.33 and a low of $1.33. This represents a -84.71% decline from the last price of $8.70.

IMA Stock Rating

ImageneBio stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (80.00%), 1 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 1 4 Strong Sell Sell Hold Buy Strong Buy

IMA Price Target Upside V Benchmarks

TypeNameUpside
StockImageneBio-84.71%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$8.70$8.70$8.70
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25-1---1
Sep, 25-1---1
Aug, 25-1---1
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 29, 2024David NierengartenWedbush$1.33$1.64-18.90%-84.71%
May 29, 2024David NierengartenWedbush$2.00$1.3350.38%-77.01%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 29, 2024William BlairOutperformOutperformhold
May 29, 2024Cowen & Co.BuyBuyhold
May 29, 2024Wells FargoUnderweightdowngrade
May 29, 2024WedbushOutperformNeutraldowngrade
May 29, 2024H.C. WainwrightBuyBuyhold
May 14, 2024WedbushBuyOutperforminitialise
Mar 19, 2024WedbushBuyBuyhold
Jan 19, 2024WedbushOutperformOutperformhold
Sep 22, 2023WedbushOutperforminitialise
Mar 15, 2023Credit SuisseOutperformOutperformhold

Financial Forecast

EPS Forecast

$-20 $-16 $-12 $-8 $-4 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-1.63$-1.02-----
Avg Forecast$-19.48$-13.29$-2.95$-3.32$-6.12$-7.24$-5.41
High Forecast$-19.48$-13.29$-0.87$-3.32$-6.12$-7.24$-5.41
Low Forecast$-19.48$-13.29$-5.03$-3.32$-6.12$-7.24$-5.41
Surprise %-91.63%-92.33%-----

Revenue Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$9.16M------
Avg Forecast$11.87M$3.50M-----
High Forecast$11.87M$3.50M-----
Low Forecast$11.87M$3.50M-----
Surprise %-22.84%------

Net Income Forecast

$-950M $-760M $-570M $-380M $-190M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-68.17M$-49.23M-----
Avg Forecast$-940.12M$-641.23M$-142.56M$-160.16M$-295.50M$-349.39M$-261.08M
High Forecast$-940.12M$-641.23M$-41.75M$-160.16M$-295.50M$-349.39M$-261.08M
Low Forecast$-940.12M$-641.23M$-242.94M$-160.16M$-295.50M$-349.39M$-261.08M
Surprise %-92.75%-92.32%-----

IMA Forecast FAQ

Is ImageneBio stock a buy?

ImageneBio stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that ImageneBio is a favorable investment for most analysts.

What is ImageneBio's price target?

ImageneBio's price target, set by 5 Wall Street analysts, averages $1.33 over the next 12 months. The price target range spans from $1.33 at the low end to $1.33 at the high end, suggesting a potential -84.71% change from the previous closing price of $8.7.

How does ImageneBio stock forecast compare to its benchmarks?

ImageneBio's stock forecast shows a -84.71% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for ImageneBio over the past three months?

  • October 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is ImageneBio’s EPS forecast?

ImageneBio's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.95, marking a 189.22% increase from the reported $-1.02 in 2024. Estimates for the following years are $-3.32 in 2026, $-6.12 in 2027, $-7.24 in 2028, and $-5.41 in 2029.

What is ImageneBio’s revenue forecast?

ImageneBio's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $0, followed by $0 for 2027, $0 for 2028, and $0 for 2029.

What is ImageneBio’s net income forecast?

ImageneBio's net income forecast for the fiscal year ending in December 2025 stands at $-143M, representing an 189.55% increase from the reported $-49.234M in 2024. Projections indicate $-160M in 2026, $-296M in 2027, $-349M in 2028, and $-261M in 2029.